Skickas . Fri frakt för medlemmar vid köp för minst 249 kr.
Nervous system diseases and disorders are highly prevalent and substantially contribute to the overall disease burden. Despite significant information provided by the use of animal models in the understanding of the biology of nervous system disorders and the development of therapeutics; limitations have also been identified. Treatment options that are high in efficacy and low in side effects are still lacking for many diseases and, in some cases are nonexistent. A particular problem in drug development is the high rate of attrition in Phase II and III clinical trials. Why do many therapeutics show promise in preclinical animal models but then fail to elicit predicted effects when tested in humans? On March 28 and 29, 2012, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened the workshop "Improving Translation of Animal Models for Nervous System Disorders" to discuss potential opportunities for maximizing the translation of new therapies from animal models to clinical practice.The primary focus of the workshop was to examine mechanisms for increasing the efficiency of translational neuroscience research through discussions about how and when to use animal models most effectively and then best approaches for the interpretation of the data collected. Specifically, the workshop objectives were to: discuss key issues that contribute to poor translation of animal models in nervous system disorders, examine case studies that highlight successes and failures in the development and application of animal models, consider strategies to increase the scientific rigor of preclinical efficacy testing, explore the benefits and challenges to developing standardized animal and behavioral models. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary also identifies methods to facilitate development of corresponding animal and clinical endpoints, indentifies methods that would maximize bidirectional translation between basic and clinical research and determines the next steps that will be critical for improvement of the development and testing of animal models of disorders of the nervous system.
1 Front Matter; 2 1 Introduction and Overview; 3 2 Evaluation of Current Animal Models; 4 3 Translation from Animal Models to the Clinic: Case Examples from Neuroscience Research; 5 4 Perspectives on Standardization; 6 5 Perspectives on Corresponding Animal and Clinical Endpoints; 7 6 Addressing the Translational Disconnect; 8 7 Summary of Workshop Topics; 9 Appendix A: References; 10 Appendix B: Workshop Agenda; 11 Appendix C: Registered Attendees
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Sciences Policy, African Science Academy Development Initiative, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Patricia A. Cuff, Theresa M. Wizemann, Diana E. Pankevich
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Theresa Wizemann, Diana E. Pankevich
Institute of Medicine, Board on Global Health, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Theresa M. Wizemann, Sheena M. Posey Norris, Diane E. Pankevich
National Research Council, Division on Earth and Life Studies, Board on Life Sciences, Institute of Medicine, Board on Health Sciences Policy, Committee on the Use of Chimpanzees in Biomedical and Behavioral Research, Jeffrey P. Kahn, Marilee K. Shelton-Davenport, Diana E. Pankevich, Bruce M. Altevogt
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Miriam Davis, Diana E. Pankevich
National Research Council, Institute of Medicine, Division on Earth and Life Studies, Institute for Laboratory Animal Research, Policy and Global Affairs, and Law Committee on Science, Technology, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Anne-Marie Mazza, Theresa M. Wizemann, Diana E. Pankevich
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Clare Stroud, Christopher Palmer, Sheena M. Posey Norris
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Bruce M. Altevogt, Diana E. Pankevich, Theresa Wizemann
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Sheena M. Posey Norris, Diana E. Pankevich, Miriam Davis, Bruce M. Altevogt
Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous Systems Disorders, Bruce M. Altevogt, Theresa Wizemann, Diana E. Pankevich